Login to Your Account



STEALING THE SHOW AT THE J.P. MORGAN HEALTHCARE CONFERENCE

Yes, ‘Sirna’: $700M to Alnylam in bigger deal with Genzyme

By Randy Osborne
Staff Writer

Tuesday, January 14, 2014
SAN FRANCISCO – As Wall Street calmed in the wake of Alnylam Pharmaceuticals Inc.’s double shot of news – a $700 million expansion of the pact with Sanofi SA’s Genzyme unit, and the $175 million buyout of RNAi peer Sirna Therapeutics Inc. – investor eyes turned to the prospects of ALN-TTR-sc, the subcutaneous therapy targeting transthyretin (TTR), in Phase II trials for familial amyloid cardiomyopathy (FAC).

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription